BNKL has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BNKL has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Bionik Laboratories's enterprise value is $0.00 Mil. Bionik Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 was $-4.78 Mil. Therefore, Bionik Laboratories's EV-to-EBITDA for today is 0.00.
The historical rank and industry rank for Bionik Laboratories's EV-to-EBITDA or its related term are showing as below:
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-10-31), Bionik Laboratories's stock price is $1.0E-5. Bionik Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.720. Therefore, Bionik Laboratories's PE Ratio (TTM) for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
The historical data trend for Bionik Laboratories's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionik Laboratories Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Mar16 | Mar17 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | Mar23 | |||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | -2.18 | -0.37 | -1.31 | -0.06 | -0.99 |
Bionik Laboratories Quarterly Data | ||||||||||||||||||||
Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | |
EV-to-EBITDA | Get a 7-Day Free Trial | -0.06 | -0.56 | -0.25 | -1.09 | -0.99 |
For the Medical Care Facilities subindustry, Bionik Laboratories's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, Bionik Laboratories's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bionik Laboratories's EV-to-EBITDA falls into.
Bionik Laboratories's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 0.000 | / | -4.776 | |
= | 0.00 |
Bionik Laboratories's current Enterprise Value is $0.00 Mil.
Bionik Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.78 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionik Laboratories (OTCPK:BNKL) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bionik Laboratories's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 1.0E-5 | / | -0.720 | |
= | At Loss |
Bionik Laboratories's share price for today is $1.0E-5.
Bionik Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.720.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Bionik Laboratories's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Remi Gaston-dreyfus | director, 10 percent owner | 46 RUE PIERRE CHARRON, PARIS I0 75008 |
Charles Matine | director | 7 RUE GUSTAVE, FLAUBERT, PARIS I0 75017 |
Andre-jacques Auberton-herve | director, officer: Chairman | 18 CHEMIN DE LA VIERGE NOIRE, LA TRONCHE I0 38700 |
Daniel Gonsalves | officer: Executive Vice President & CFO | 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472 |
Loren W. Wass | officer: See Remarks | 34 HOG HILL ROAD, PEPPERELL MA 01463 |
Joseph R Martin | director | |
Audrey Thevenon | director | 4500 WESTBROOK LANE, KENSINGTON MD 20895 |
Peter Gerald Malone | director | |
Russo Richard Paul Jr | officer: Chief Financial Officer | 20 PLUNKETT WAY, TEWKSBURY MA 01876 |
Renaud Bertrand Maloberti | officer: Chief Commercial Officer | 10 ACORN WAY, GEORGETOWN MA 01833 |
Timothy A. Mccarthy | officer: Chief Commercialization Office | C/O BIONIK, 483 BAY STREET, N105, TORONTO A6 M5G 2C9 |
Eric Michel Dusseux | director | 1 RUE DU CAPOT, CALUIRE-ET-CUIRE I0 69300 |
Jules Marc Fried | officer: VP - U.S. Operations | C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472 |
Hermano Igo Krebs | officer: Chief Science Officer | C/O INTERACTIVE MOTION TECHNOLOGIES INC., 80 COOLIDGE HILL ROAD, WATERTOWN MA 02472 |
Marc Mathieu | director | 716 BROOKS AVENUE, VENICE CA 90291 |
From GuruFocus
By PRNewswire PRNewswire • 10-24-2018
By PRNewswire PRNewswire • 03-20-2018
By PRNewswire PRNewswire • 10-29-2018
By PRNewswire PRNewswire • 05-16-2018
By PRNewswire PRNewswire • 04-04-2018
By PRNewswire PRNewswire • 06-21-2018
By ACCESSWIRE ACCESSWIRE • 09-01-2022
By PRNewswire PRNewswire • 09-13-2018
By PRNewswire PRNewswire • 10-30-2018
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.